Jemperli (dostarlimab-gxly)

Results from the RUBY and NRG-GY018 trials show that combining dostarlimab or pembrolizumab with platinum-based chemotherapy improves survival in patients with untreated advanced disease...Overcoming this resistance requires combination strategies, such as using anti-angiogenic agents like lenvatinib with immune checkpoint inhibitors, as shown in the KEYNOTE-775 trial...As molecular monitoring via liquid biopsy and the use of antibody-drug conjugates (ADCs) evolve, the personalization of immunotherapy continues to progress. This review examines current clinical evidence and the mechanisms of resistance to define the future of precision medicine in endometrial cancer.

P1/2, N=34, Active, not recruiting, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2027 --> Mar 2027

At 4 years, RUBY demonstrated sustained remission and long-term survival benefit, suggesting the potential for curative intent with dostarlimab+CP in patients with dMMR/MSI-H primary advanced or recurrent EC.

P1/2, N=1000, Recruiting, Oslo University Hospital HF | N=6000 --> 1000

The largest adequately powered signals were observed for pembrolizumab (ROR 18.34, n = 258), nivolumab (ROR 18.65, n = 256), atezolizumab (ROR 22.22, n = 132), and ipilimumab (ROR 15.11, n = 73); cemiplimab (ROR 46.89), relatlimab (ROR 44.68), and dostarlimab (ROR 33.48) produced high-magnitude estimates with smaller case counts. The DM phenotype is more consistently disproportionate than PM across classes, with mechanistic plausibility given PD-L1's role in restraining interferon-producing plasmacytoid dendritic cells. The immune-mediated myositis MedDRA term captures the most statistically robust signal, reflecting a distinct ICI-associated coding pattern in spontaneous reporting.

P1, N=845, Recruiting, GlaxoSmithKline | N=590 --> 845 | Trial completion date: May 2027 --> Jun 2029 | Trial primary completion date: Sep 2026 --> Oct 2028

P1/2, N=305, Recruiting, GlaxoSmithKline | Trial completion date: Apr 2028 --> Oct 2028 | Trial primary completion date: Dec 2027 --> Jun 2027

The patient is currently undergoing palliative chemotherapy with carboplatin, paclitaxel, and dostarlimab, continues on lifelong anticoagulation, and receives comprehensive pain management. This case underscores the diagnostic complexity of cardiac masses, particularly in patients with malignancy. It highlights the critical role that multimodality imaging plays in resolving complex diagnostic dilemmas and emphasizes the importance of a collaborative approach in managing such patients.

SG demonstrated encouraging efficacy in a pretreated population that included biologically aggressive recurrent EC. Adverse events were consistent with the known safety profile.

Post-operatively, she received six cycles of carboplatin, paclitaxel, and dostarlimab every three weeks, followed by maintenance dostarlimab. This case illustrates that aggressive multimodal therapy including immune checkpoint inhibition may achieve durable disease control in advanced-stage MMR-deficient uterine LCNEC. While the relative contributions of surgery, chemotherapy, radiation, and immunotherapy cannot be separated, the favorable outcome supports further investigation of immunotherapy in rare high-grade endometrial neuroendocrine carcinomas and underscores the importance of including these histologies in clinical trials.

P1/2, N=208, Active, not recruiting, GlaxoSmithKline | Phase classification: P2 --> P1/2

P2, N=35, Recruiting, Hopital Foch | Active, not recruiting --> Recruiting